Checkpoint Therapeutics to Participate in the H.C. Wainwright Global Investment Conference

Rhea-AI Summary

Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) announced that CEO James Oliviero will present a company overview at the H.C. Wainwright Global Investment Conference on May 25, 2022, at 3:00 p.m. ET. The management team will also engage in one-on-one meetings. A live webcast of the presentation can be accessed on Checkpoint's website for about 30 days post-event. Checkpoint focuses on novel oncology treatments, including the evaluation of cosibelimab and olafertinib for solid tumor cancers.

WALTHAM, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will present a company overview at the H.C. Wainwright Global Investment Conference, on Wednesday, May 25, 2022, at 3:00 p.m. ET. Checkpoint management will also participate in one-on-one meetings during the conference.

A live webcast of the presentation will be available on the Investor Relations Calendar page under News & Events, located within the Investors section of Checkpoint’s website, https://ir.checkpointtx.com/event-calendar/default.aspx, for approximately 30 days following the meeting.

About Checkpoint Therapeutics
Checkpoint Therapeutics, Inc. (“Checkpoint”) is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. Checkpoint is evaluating its lead antibody product candidate, cosibelimab, a potential best-in-class anti-PD-L1 antibody licensed from the Dana-Farber Cancer Institute, in an ongoing global, open-label, multicohort Phase 1 clinical trial in checkpoint therapy-naïve patients with selected recurrent or metastatic cancers, including ongoing cohorts in locally advanced and metastatic cutaneous squamous cell carcinoma (“cSCC”) intended to support one or more applications for marketing approval. Following positive topline results in metastatic cSCC, Checkpoint intends to submit a Biologics License Application for this indication later this year. Checkpoint is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib (formerly CK-101), a third-generation epidermal growth factor receptor (“EGFR”) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer. Checkpoint is headquartered in Waltham, MA and was founded by Fortress Biotech, Inc. (NASDAQ: FBIO). For more information, visit www.checkpointtx.com.

Company Contacts:
Jaclyn Jaffe and Bill Begien
Checkpoint Therapeutics, Inc.
(781) 652-4500
ir@checkpointtx.com

Investor Relations Contact:
Ashley R. Robinson
Managing Director, LifeSci Advisors, LLC
(617) 430-7577
arr@lifesciadvisors.com

Media Relations Contact:
Katie Kennedy
Gregory FCA
(610) 731-1045
Checkpoint@gregoryfca.com

FAQ

When will Checkpoint Therapeutics present at the H.C. Wainwright Global Investment Conference?

Checkpoint Therapeutics will present on May 25, 2022, at 3:00 p.m. ET.

Who is presenting for Checkpoint Therapeutics at the conference?

James Oliviero, the President and CEO, will present for Checkpoint Therapeutics.

How can I watch the presentation from Checkpoint Therapeutics?

The presentation will be available via live webcast on Checkpoint's Investor Relations page for approximately 30 days.

What is Checkpoint Therapeutics focusing on in their research?

Checkpoint Therapeutics is focused on developing novel treatments for solid tumor cancers, particularly cosibelimab and olafertinib.

What is the ticker symbol for Checkpoint Therapeutics?

The ticker symbol for Checkpoint Therapeutics is CKPT.